BPC-157 is a synthetic pentadecapeptide — a fifteen-amino-acid chain — whose sequence corresponds to a fragment identified in human gastric juice. Its reported effects come from preclinical work in animals and cells; human data are extremely limited. It is not approved by any regulator, for any use, anywhere.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published research actually reports, clearly separating animal and laboratory findings from human ones, explains why no reliable human half-life exists for this compound, and describes what a clean record holds. It contains no dose figures and no schedule, and the section further down explains why that is deliberate rather than an omission.
| Property | Value |
|---|---|
| Type | Synthetic pentadecapeptide (fifteen-amino-acid chain); sequence corresponds to a fragment identified in human gastric juice |
| Evidence base | Preclinical — animal and in-vitro (cell) studies. Human data extremely limited: a few small pilot studies, no large-scale trials |
| Half-life | No reliable human half-life has been published |
| Development status | Investigational research peptide |
| Regulatory status | Not approved by any regulator for any indication |
BPC-157 (“Body Protection Compound”) is a pentadecapeptide isolated from human gastric juice, and it has been reported to have wide-ranging beneficial effects in preclinical models that mimic conditions such as tissue injury, inflammatory bowel disease and nervous-system disorders (Józwiak et al., 2025). The key qualifier is preclinical: these are animal and cell studies, not results in people.
The use BPC-157 is best known for online is musculoskeletal healing. A 2025 narrative review of exactly that question found broad preclinical support in animals but concluded that “human data are extremely limited” — only a handful of small pilot studies have examined it in humans, with no rigorous, large-scale trials — and that BPC-157 “should be considered investigational” (McGuire et al., 2025).
On status, the literature is consistent. BPC-157 has not been approved for use in standard medicine by the FDA or other regulatory authorities, a point reviewers attribute directly to the absence of comprehensive human clinical studies (Józwiak et al., 2025). A 2026 review of injectable peptides lists it among unapproved compounds that lack an established human safety profile (Moiz et al., 2026). None of that makes BPC-157 uninteresting as a research peptide; it does mean that anything presenting a settled human dose or a definite benefit is running well ahead of the evidence.
A half-life is the time it takes for half of what is present to clear, and it is the single number a decay curve is built from. For BPC-157 it does not exist: no reliable human half-life has been published, because the evidence base is preclinical and no human pharmacokinetic study has established how quickly the peptide clears from a person.
The practical consequence is simple and worth stating plainly: you cannot chart a decay curve for BPC-157, because there is no trustworthy value to put into one. Any figure circulating online as its “human half-life” is not drawn from a human study, because none has been published — it is extrapolated from animal work or simply asserted. A record that invents a half-life inherits that invention. What you can record reliably does not depend on a half-life at all: the dated history of when you logged, what figure you used, and when anything changed. That history is honest; a fabricated curve only looks like it is.
A lyophilized, or freeze-dried, powder is the stable, shelf-storable form of a peptide; reconstituting it with a diluent trades that stability for a solution that needs more care. Standard product labeling for lyophilized peptide injectables bears this out. The US FDA label for glucagon, a lyophilized peptide, stores the powder at controlled room temperature and protected from light, and directs that once reconstituted the solution be used without delay with any unused portion discarded (US FDA label, glucagon for injection).
Different products set different limits after reconstitution, and material supplied without a preservative is less forgiving again. The governing instruction is whatever the source of your own material specifies — this page supplies no figure for it. For record-keeping, note the form you received, the diluent and volume if you mixed it yourself, and the date you reconstituted, so the age of the vial is never a guess.
Tracking BPC-157 in Pepti is the same disciplined logging it applies to anything else. The fields that matter are the date and time, the figure you already have in the unit you think in, the injection site, and — if you reconstituted it yourself — the diluent volume and the resulting concentration.
The reconstitution calculator converts the figure you already have into a draw volume, expressed only as variables: the concentration is the peptide amount in the vial divided by the volume of water you add; the volume to draw is your figure divided by that concentration; and the syringe units are that volume multiplied by one hundred on a U-100 syringe. Those are the relationships, not a recommendation — you supply the figure, Pepti does the arithmetic. The injection site rotation guide sets out the fixed 12-site sequence Pepti steps through, so each injection lands away from the last. And because no reliable human half-life exists for BPC-157, the half-life decay calculator has nothing trustworthy to chart here: it only ever plots a value you type in, and for this compound there is no sound human value to enter.
BPC-157 is an unapproved research peptide. There is no approved label for it anywhere in the world, which means there is no authorised dose, no approved titration path, and no clinician-facing guidance outside research settings. Any figure published as a “typical dose” for it is not drawn from an approved source, because no such source exists. It comes from forum consensus, from vendor copy, or from someone’s reading of an animal protocol — none of which carries the authority its typographic confidence implies.
Pepti does not supply the figure, and it will not, for this compound or any other. Pages that publish dose tables for unapproved compounds are publishing folklore with the typography of evidence — the numbers look authoritative because they sit in a table, not because anything stands behind them. The figure belongs to you and whoever directs your use. The arithmetic is what we are for.
A record worth keeping is one you can still read honestly months later. For BPC-157 it holds the following.
The reconstitution calculator turns the figure you already have into a draw volume and a count of doses per vial, and a peptide tracker app keeps every one of those entries on a single timeline rather than scattered across notes and memory.
BPC-157, sometimes called Body Protection Compound 157, is a synthetic pentadecapeptide - a chain of fifteen amino acids - whose sequence corresponds to a fragment identified in human gastric juice. Its reported effects come almost entirely from laboratory and animal studies, not from trials in people. It is not an approved medicine.
No. BPC-157 has not been approved for use in standard medicine by the FDA or other regulatory authorities, and published reviews describe it as investigational. Human data are extremely limited - only a few small pilot studies exist, with no large-scale trials. That is the honest status, whatever a seller implies.
No reliable human half-life has been published. The published evidence is preclinical, and no human pharmacokinetic study establishes how quickly it clears. A figure presented as its human half-life is not coming from a human study, because none exists, so this page gives none.
It depends on the form you have. BPC-157 is commonly supplied as a lyophilized, or freeze-dried, powder that stays inert until a diluent is added, though some material is sold already in solution. A record that does not say which form it describes becomes ambiguous later, so note the form and, if you mixed it yourself, the diluent volume you added.
No. Pepti supplies no dose figures for BPC-157 or anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the injection-site sequence. The arithmetic is ours - the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend BPC-157 or any other substance, and it provides no dose figure, no titration amount, and no schedule. BPC-157 is an unapproved research peptide and is not approved for any use.
The Pepti peptide tracker for iPhone keeps the log, the injection-site sequence, the vial count and your observations in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store